A Non-inferiority Clinical Trial to Compare Efficacy and Safety of Abobotulinumtoxin A (Espad Pharmed) Versus AbobotulinumtoxinA (Dysport®, Ipsen Co.) for Correction of Moderate to Severe Glabellar Lines
Clinical trial NCT06946160 · COMPLETED
Trial details
- NCT number
- NCT06946160
- Sponsor
- Espad Pharmed
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2024-05-28
- Primary completion
- 2025-02-18
- Enrollment
- 146
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.